期刊
JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA
卷 13, 期 2, 页码 259-268出版社
SPRINGER/PLENUM PUBLISHERS
DOI: 10.1007/s10911-008-9079-3
关键词
alternative splicing; epidermal growth factor; estrogen receptor; HER4; neuregulins; targeted therapeutics
Members of the ErbB subfamily of receptor tyrosine kinases are important regulators of normal mammary gland physiology, and aberrations in their signaling have been associated with breast tumorigenesis. Therapeutics targeting epidermal growth factor receptor (EGFR = ErbB1) or ErbB2 in breast cancer have been approved for clinical use. In contrast, relatively little is known about the biological significance of ErbB4 signaling in breast cancer. This review focuses on recent advances in our understanding about the role of ErbB4 in breast carcinogenesis, as well as in the potential clinical relevance of ErbB4 in breast cancer prognostics and therapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据